Allowing for the small patient numbers, the response rates in ASPS stood out as among the most sensitive STS subtypes—2/4 (50%) of the ASPS patients responded to anti-PD-L1 therapy in an MD Anderson retrospective series of CPIs in the treatment of STS [26], while a response was seen in the only patient with ASPS to receive nivolumab monotherapy in the ALLIANCE A091401 trial [18]. The gene discussed is CD274; the disease is telomere syndrome.